Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2013 Jun 1.
Published in final edited form as: Cytometry A. 2012 Mar 19;81(6):450–452. doi: 10.1002/cyto.a.22035

OMIP-008: Measurement of Th1 and Th2 cytokine polyfunctionality of human T cells

Cindy L Zuleger 1, Mark R Albertini 1,2,3,*
PMCID: PMC3418807  NIHMSID: NIHMS363148  PMID: 22431369

Abstract

Purpose and Appropriate Sample Types

This panel was optimized to assess CD4+ and CD8+ T cell responses to various tumor antigens from melanoma patients. The panel was tested on single-cell derived T cell isolates (SCD-T) and T cell lines derived from peripheral blood mononuclear cells (PBMC) from melanoma patients, T cell lines from the tumor environment of melanoma patients, and fresh and cryopreserved PBMC (healthy donors). Staining can be performed in 96-well plates for high-throughput.

Keywords: Immunophenotype, T cells, intracellular cytokine staining, melanoma

Background

The T cell response to human melanoma is broad, encompassing both effector and regulatory T cell populations with diverse functional profiles (1). Tumor specific T cells with cytokine profiles that do not follow the standard Th1/Th2 dichotomy have been demonstrated (2,3). These descriptions include tumor antigen-specific effector and regulatory T cells that co-produce Th1 and Th2 cytokines. Thus, immunological monitoring of T cells from melanoma patients needs to assess a wide spectrum of functions and often has access to only a limited number of cells. To provide a tool for this immunological monitoring, we developed a panel of Ab-conjugates for assessing cytokine profiles that cross “traditional” T cell subset boundaries. As such, this panel would be useful for those interested in human T cells with a mixed cytokine profile, such as induced regulatory T cells, IL-10+ CD8+ T cells, T cells involved in allergic responses, etc. Further, it should be useful for samples with limited cell numbers, such as tumor biopsies, fine-needle aspirations, or cerebral spinal fluid, as well as samples from which multiple separate samples for Th1 versus Th2 intracellular cytokine staining are not possible. This panel was developed following guidelines described previously (4). To maximize sensitivity, the brightest fluorochromes were reserved for IL-2, IL-4, IL-10, IFN-γ and TNF-αA dump channel was used to exclude dead cells, B cells, and monocytes/macrophages. Next, testing a collection of Ab-conjugates optimized the differentiation of T cell subsets. APC-Cy7 and Quantum dot (QD) 605 were selected for discrimination of CD4 and CD8, respectively, because of their stability in this panel.

CD3 was labeled after fixing and permeabilizing the cells to ensure that activated T cells having down-regulated their TCR/CD3 complex were included in the analysis (4). To permit resolution of CD4 following activation of T cells with PMA and ionomycin (used as a mitogenic control), CD4 was also labeled post-fixation/permeabilization for all samples. Specificity of the cytokine staining is demonstrated by reduced staining following blocking steps prior to intracellular staining with the fluorochrome-conjugated anti-cytokine reagents: i) the surface-stained, fixed and permeabilized cells are blocked with purified anti-cytokine antibodies of the identical clones; and ii) the fluorochrome-conjugated reagents are blocked with recombinant human cytokine. These blocking steps typically reduce cytokine+ staining to background levels, or to a level allowing unambiguous gate setting, and as such these fully stained and blocked samples are used to determine placement of cytokine+ gates. This provides an alternative to individual FMO controls for each cytokine, which may not be feasible due to limited cell numbers from patient samples. The level of autofluorescence of the T cell lines has not been a substantial confounder in these experiments and we have not noted marked differences between the autofluorescence of cultured as compared to uncultured T cells from healthy donors.

Human Subjects

The Health Sciences Institutional Review Board that serves both the William S. Middleton Memorial Veterans Hospital and the University of Wisconsin-Madison approved this study (Human Subjects Protocol # 1992-031). Written informed consent was obtained from the participants in this study.

Similarity to Published OMIPs

OMIP-001 was designed to detect cytokine-producing T cells, including IL-2, IFN-γ, and TNF-α (5). Our panel extends OMIP-001 with the addition of IL-4 and IL-10, thus broadening its potential application for the discrimination of T cells exhibiting traditional Th1 and Th2 responses, as well as those with unconventional cytokine profiles.

Supplementary Material

Supp Fig 2a
Supp Fig 2b
Supp Fig 3a
Supp Fig 3b
Supp Fig 4a
Supp Fig 4b
Supp Fig 5
Supp Fig 6a
Supp Fig 6b
Supp Fig 7
Supp Fig S1a
Supp Fig S1b
Supp Material

Figure 1.

Figure 1

Figure 1

Figure 1

Gating strategy and example staining. A. Cells in the singlet gate are selected, live CD3+ CD14 CD19 cells identified, followed by exclusion of dye aggregates (grey box) and after gating on small lymphocytes, CD4+ and CD8+ T cells are selected for further analysis. CD4+ and CD8+ T cells positive for individual cytokines are separately gated and subsequently, a Boolean gate encompassing all combinations (25) of cytokine+/− T cells is created. The median fluorescence intensity (MFI) of cytokine+ T cells is evaluated, providing a measure of the magnitude of the response. B, C. Determination of cytokine+ T cells following gating described in (A). B. Shown is a CD4+ T cell line derived from the tumor of a melanoma patient stimulated with an allogeneic melanoma tumor cell line. The frequency of T cells positive for IFN-γ, TNF-α, IL-2, or IL-10 following antigenic stimulation was significantly greater than unstimulated T cells. C. Shown is a CD4+ T cell line derived from the tumor of a melanoma patient stimulated with an autologous melanoma tumor cell line. The frequency of T cells positive for TNF-α, IL-10, or IL-4 following antigenic stimulation was significantly greater than unstimulated T cells. The T cell lines in B. and C. are from two different patients stimulated with the same melanoma cell line. Data in B. and C. are presented as low-resolution dot plots. Robust cytokine responses from mitogen-stimulated PBMC are presented in Online Fig.7.

Table 1.

Summary table for application of OMIP-008

Purpose T cell cytokine production following in vitro stimulation
Species Human
Cell types PBMC, T cell clones/lines, tumor-resident T cell lines
Cross references OMIP-001

Table 2.

Reagents used for OMIP-008

SPECIFICITY CLONE FLUOROCHROME PURPOSE
IL-2 MQ1-17H12 PerCP-Cy5.5 Function
IL-4 8D4-8 Ax488
IL-10 JES3-9D7 PE
IFN-γ B27 APC
TNF-α MAb11 PE-Cy7
CD3 UCHT1 Ax700 Lineage
CD4 RPA-T4 APC-Cy7
CD8 3B5 QD605
CD14 M5E2 PacBlu Dump
CD19 HIB19 eFluor450
Dead cells - ViViD

PerCP, peridinin chlorophyll protein; Cy, cyanine; Ax, Alexa; PE, R-phycoerythrin; APC, allophycocyanin; QD, quantum dot; Bi, biotin; PacBlu, pacific blue; ViViD, LIVE/DEAD fixable violet dead cell stain.

Acknowledgments

Grant Sponsors: This material is based on work supported by the Office of Research and Development, Biomedical Laboratory Research and Development Service, Department of Veterans Affairs; grant P30 CA014520 from the National Cancer Institute; the Gretchen and Andrew Dawes Melanoma Research Fund; Ann’s Hope Foundation; the Jay Van Sloan Memorial from the Steve Leuthold Family; and the Tim Eagle Memorial.

Footnotes

The authors have no financial or other conflicts of interests to disclose related to this publication. The contents do not represent the views of the Dept. of Veterans Affairs or the United States Government.

References

  • 1.Appay V, Jandus C, Voelter V, Reynard S, Coupland SE, Rimoldi D, Lienard D, Guillaume P, Krieg AM, Cerottini JC, Romero P, Leyvraz S, Rufer N, Speiser DE. New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site. J Immunol. 2006;177:1670–1678. doi: 10.4049/jimmunol.177.3.1670. [DOI] [PubMed] [Google Scholar]
  • 2.Wang HY, Lee DA, Peng G, Guo Z, Li Y, Kiniwa Y, Shevach EM, Wang RF. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity. 2004;20:107–118. doi: 10.1016/s1074-7613(03)00359-5. [DOI] [PubMed] [Google Scholar]
  • 3.Kyte JA, Trachsel S, Risberg B, thor Straten P, Lislerud K, Gaudernack G. Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination. Cancer Immunol Immunother. 2009;58:1609–1626. doi: 10.1007/s00262-009-0670-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.McLaughlin BE, Baumgarth N, Bigos M, Roederer M, De Rosa SC, Altman JD, Nixon DF, Ottinger J, Oxford C, Evans TG, Asmuth DM. Nine-color flow cytometry for accurate measurement of T cell subsets and cytokine responses. Part I: Panel design by an empiric approach. Cytometry A. 2008;73A:400–410. doi: 10.1002/cyto.a.20555. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Mahnke YD, Roederer M. OMIP-001: Quality and phenotype of Ag-responsive human T-cells. Cytometry A. 2010;77A:819–820. doi: 10.1002/cyto.a.20944. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supp Fig 2a
Supp Fig 2b
Supp Fig 3a
Supp Fig 3b
Supp Fig 4a
Supp Fig 4b
Supp Fig 5
Supp Fig 6a
Supp Fig 6b
Supp Fig 7
Supp Fig S1a
Supp Fig S1b
Supp Material

RESOURCES